From: Telomerase reverse transcriptase gene amplification in hematological malignancies
Parameter | AML patients (N = 15) |
---|---|
Age (mean ± SD) | 47.2 ± 7.5 |
Gender, N (%) | |
Male | 9 (60%) |
Female | 6 (40%) |
Presentation, N (%) | |
DNV | 11 (73.3%) |
Relapse | 4 (26.7%) |
Lymphadenopathy, N (%) | 8 (53.3%) |
Splenomegaly, N (%) | 4 (26.7%) |
Hepatomegaly, N (%) | 3 (20%) |
WBC count (× 109/l) (mean ± SD) | 8.8 ± 5.9 |
Hb level (g/dl) (mean ± SD) | 11.3 ± 2.4 |
Platelet count (× 109/l) (mean ± SD) | 110 ± 38 |
BM blasts % (mean ± SD) | 68 ± 21 |
Karyotype, N (%) | |
Normal | 8 (53.3%) |
Numerical aberrations | 4 (26.7%) |
Structural aberrations | 3 (20%) |
TERT amplification, N (%) | 8 (53.3%) |
Prognosis, N (%) | |
Good | 8 (53.3%) |
Intermediate | 3 (20.1%) |
Bad | 4 (26.6%) |